









Markets
/
Stocks
/
nasdaq-akro
/

Akero Therapeutics Inc

AKRO

45.220USD

-0.980-2.12%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

3.61BMarket Cap

LossP/E TTM



Akero Therapeutics Inc

45.220

-0.980-2.12%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

198 / 506

Overall Ranking

322 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 13 analysts

Buy

Current Rating

74.273

Target Price

+60.76%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Akero Therapeutics, Inc. is a clinical-stage company. The Company is developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH), a disease without any approved therapies. Efruxifermin (EFX), is its lead product candidate for MASH, which is being evaluated in the ongoing phase IIb SYMMETRY, phase III SYNCHRONY Histology, and phase III SYNCHRONY real-world studies. The phase III SYNCHRONY program builds on the results of two phase IIb clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with cirrhosis due to MASH. EFX is an analog of fibroblast growth factor 21 (FGF21), which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. EFX is designed to offer convenient once-weekly dosing.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 124.99.

Fairly Valued

The company’s latest PE is -11.86, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 87.62M shares, decreasing 0.71% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 4.52M shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-19

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.93.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -12.12, which is -34.69% below the recent high of -7.91 and -13.73% above the recent low of -13.78.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 198/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.50, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Akero Therapeutics Inc is 75.00, with a high of 109.00 and a low of 49.00.

Score

Industry at a Glance

Previous score

8.50

Change

Support & Resistance

No Data

Analyst Rating

Based on 13 analysts

Buy

Current Rating

74.273

Target Price

+60.76%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Akero Therapeutics Inc

AKRO

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 7.17, which is higher than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 49.86 and the support level at 42.15, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.17

Change

-0.2

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.363

Neutral

RSI(14)

47.713

Neutral

STOCH(KDJ)(9,3,3)

50.702

Buy

ATR(14)

2.043

Low Volatility

CCI(14)

85.580

Neutral

Williams %R

43.257

Buy

TRIX(12,20)

-0.486

Sell

StochRSI(14)

81.257

Buy

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

43.810

Buy

MA10

43.988

Buy

MA20

45.297

Sell

MA50

48.164

Sell

MA100

48.597

Sell

MA200

43.747

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 109.91%, representing a quarter-over-quarter decrease of 1.68%. The largest institutional shareholder is The Vanguard, holding a total of 4.52M shares, representing 5.65% of shares outstanding, with 6.72% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Janus Henderson Investors

7.07M

+17.14%

General Atlantic LLC

5.23M

RTW Investments L.P.

7.42M

+8.16%

BlackRock Institutional Trust Company, N.A.

5.48M

+6.75%

The Vanguard Group, Inc.

Star Investors

4.22M

+14.25%

T. Rowe Price Associates, Inc.

Star Investors

4.73M

+11.55%

Wellington Management Company, LLP

5.94M

-19.53%

Deep Track Capital LP

3.21M

+115.45%

State Street Global Advisors (US)

2.49M

+6.80%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 4.17, which is higher than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is -0.30. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.